Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNDUCT: Neoadjuvant Durvalumab + Chemotherapy in High-risk Localized Upper Tract Urothelial Carcinoma
NCT04617756Phase 2Recruiting
- Sponsor
- CHU Nîmes
- Start
- Sep 2021
- Primary completion
- Jan 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in urothelial carcinoma (UC) (2 cohorts), sponsored by CHU Nîmes. Primary endpoint: Pathological complete response. Started Sep 2021; status: recruiting.
02
Drugs
durvalumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04617756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617756.